The construction of large-scale peptidomimetic libraries for drug screening of various immune system and inflammatory diseases is of great significance for the treatment of related diseases. CD BioSciences provides peptidomimetic library construction and drug screening services for a variety of immune system diseases and related inflammations, helping global customers to conduct related basic research and drug discovery.
Overview of Immune System
The immune system can detect and respond to a variety of pathogens, and almost all organisms have it. In particular, the human immune system has more complex defense mechanisms, including the ability to adapt to recognize pathogens more effectively. Adaptive (or acquired) immunity generates immune memory, leading to an enhanced response to subsequent encounters with the same pathogen, and this process of acquired immunity is the basis of vaccination.
Occurrence of Immune Diseases
- Immune system dysfunction can lead to autoimmune diseases, inflammatory diseases and cancer. When the immune system is not as active as normal, immunodeficiency occurs, leading to recurrent and life-threatening infections. Autoimmunity is caused by an overactive immune system attacking normal tissues as if they were foreign organisms.
Drug Discovery for Immunotherapy
- Current drugs for the treatment of immune diseases mainly focus on immunosuppressants, which are used to control autoimmune diseases or inflammation when excessive tissue damage occurs, and prevent rejection after organ transplantation. In the process of new drug discovery, peptidomimetics have attracted wide attention because of their better targeting, low cytotoxicity and high oral bioavailability.
Our Services
CD BioSciences focuses on multiple immune disease types and has constructed a high-throughput peptidomimetic drug screening library for them. Our advanced PepDomTM platform enables the design of peptidomimetic libraries based on customer specific needs and immune disease mechanisms, and enables rapid screening using drug models. The resulting peptidomimetics can be used as drug lead compounds for immune disease treatment.
We focus on multiple immune disease types and use drug models to screen, including but not limited to the following:
|
Types |
Examples |
| Autoimmune Disease |
Connective Tissue Diseases |
Rheumatoid Arthritis, Systemic Lupus Erythematosus, Dermatomyositis, Scleroderma |
| Neuromuscular Diseases |
Multiple Sclerosis, Myasthenia Gravis, Demyelinating Disease |
| Endocrine Diseases |
Primary Adrenocortical Atrophy, Chronic Thyroiditis, Juvenile Type Diabetes |
| Digestive System Diseases |
Chronic Non-Specific Ulcerative Colitis, Chronic Active Hepatitis, Habitual Anemia, Atrophic Gastritis |
| Urinary System Diseases |
Autoimmune Glomerulonephritis, Pulmonary and Renal Hemorrhagic Syndrome |
| Hematological Diseases |
Autoimmune Hemolytic Anemia, Idiopathic Thrombocytopenic Purpura, Idiopathic Leukopenia |
| Immunodeficiency Disease |
Primary Immunodeficiency Diseases |
T/B cell Immunodeficiency, Leukocyte Immunodeficiency, Complement Immunodeficiency |
| Secondary Immunodeficiency Diseases |
AIDS, Enzyme System Defect |
| Immune Proliferative Disease |
Lymphocytic Leukemia |
Acute/ Chronic Lymphoblastic Leukemia, Adult T-Lymphocyte Leukemia, Hairy Cell Leukemia |
| Lymphoma |
Hodgkin's Lymphoma、Non-Hodgkin's Lymphoma |
| Malignant Hyperplasia of Plasma Cells |
Multiple Myeloma, Macroglobulinemia, Heavy Chain Disease |
Features of Our Services
Experienced Researchers
Large-Capacity Peptidomimetic Library
Rapid in vitro Phenotype Screening
Strict Drug Efficacy Verification System
By building a high-throughput peptidomimetic screening platform, CD BioSciences is committed to screening peptidomimetic drugs for the treatment of various immune system and related inflammatory diseases. If you are interested in any aspect of the development of peptidomimetics for this class, please contact us for the best solution.
Reference
- Medzhitov, R. (2007). Recognition of microorganisms and activation of the immune response. Nature, 449(7164), 819–826.
All of our services are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.
